Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Truist Financial Corporation from $86.00 to $114.00. They now have a "buy" rating on the stock.
What Disc Medicine (IRON)'s Bitopertin Fast-Track Review and Rising R&D Spend Mean for Shareholders [Yahoo! Finance]
Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
Disc Medicine (NASDAQ:IRON) had its "buy" rating reaffirmed by analysts at Stifel Nicolaus. They now have a $125.00 price target on the stock.